This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Groen, H. J.M. Articles by Smit, E. F. Search for Related Content PubMed PubMed Citation Articles by Groen, H. J.M. Articles by Smit, E. F. Social Bookmarking                            What's this?

Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non–Cross-Resistant Schedule

From the Department of Pulmonary Diseases, University Hospital, Groningen; Vrije Universiteit, Amsterdam; and Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands.

Address reprint requests to H.J.M. Groen, MD, PhD, Department of Pulmonary Diseases, University Hospital, Hanzeplein 1, 9700 RB Groningen, the Netherlands; email h.j.m.groen{at}int.azg.nl

PURPOSE: To evaluate the efficacy of paclitaxel and carboplatin (PC) in small-cell lung cancer (SCLC) patients resistant to cyclophosphamide, doxorubicin, and etoposide (CDE).

PATIENTS AND METHODS: We performed a phase II study with PC in SCLC patients who relapsed within 3 months after first-line treatment with CDE. Paclitaxel administration (175 mg/m² by a 3-hour intravenous infusion) was followed by a 30-minute infusion of carboplatin (area under the curve 7; Chatelut formula) once every 3 weeks for five cycles. Dexamethasone, clemastine, and ranitidine were standard premedication before every cycle.

RESULTS: Included were 35 patients (median age, 59 years; 16 with limited disease and 19 with extensive disease; Eastern Cooperative Oncology Group performance status of 1; median time off treatment 6 weeks) who were previously treated with CDE (n = 33), oral etoposide (n = 2), and reinduction CDE (n = 15); only one patient had received three CDE treatments of five cycles. The CDE regimen was followed by local thoracic radiotherapy in seven patients. Hematologic toxicity of grade 3 or 4, for leukopenia was 27% and 6%, for thrombocytopenia 21% and 13%, and for anemia 17% and 0%, respectively, for a total of 132 cycles. Two patients had neutropenic fever; no toxic death occurred. Nonhematologic toxicity was paresthesia CTC grade 3, diarrhea grade 4, and myalgia grade 3 in one patient each. Reversible paresthesia (CTC grade 1 and 2) in toes and fingers was reported in 69% of patients. Thirty-four patients were assessable for response: complete response in two patients, partial response in 23 patients, stable disease in eight patients, and progressive disease in one patient (response rate, 73.5%; 95% confidence interval, 59% to 88%). One patient was found to have atypical carcinoid at pathologic review and was excluded. Median time to progression was 21 weeks (range, 3 to 40 weeks). Median survival was 31 weeks (range, 6 to 112 weeks). One-year survival was 9%.

CONCLUSION: Second-line PC in CDE-resistant SCLC patients yields a high response rate and seems non–cross-resistant to CDE. Toxicity was mild in these poor-prognosis patients.

Paclitaxel was a gift of Bristol-Myers Squibb.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Neubauer, J. Schwartz, J. Caracandas, P. Conkling, D. Ilegbodu, T. Tuttle, and L. Asmar Results of a Phase II Study of Weekly Paclitaxel Plus Carboplatin in Patients With Extensive Small-Cell Lung Cancer With Eastern Cooperative Oncology Group Performance Status of 2, or Age >= 70 Years J. Clin. Oncol., May 15, 2004; 22(10): 1872 - 1877. [Abstract] [Full Text] [PDF]

				M. J. Edelman, K. Chansky, L. E. Gaspar, B. Leigh, G. R. Weiss, S. A. Taylor, J. Crowley, R. Livingston, and D. R. Gandara Phase II Trial of Cisplatin/Etoposide and Concurrent Radiotherapy Followed by Paclitaxel/Carboplatin Consolidation for Limited Small-Cell Lung Cancer: Southwest Oncology Group 9713 J. Clin. Oncol., January 1, 2004; 22(1): 127 - 132. [Abstract] [Full Text] [PDF]

				A. Ardizzoni, C. Manegold, C. Debruyne, R. Gaafar, E. Buchholz, E. F. Smit, P. Lianes, G. ten Velde, L. Bosquee, C. Legrand, et al. European Organization for Research and Treatment of Cancer (EORTC) 08957 Phase II Study of Topotecan in Combination with Cisplatin as Second-Line Treatment of Refractory and Sensitive Small Cell Lung Cancer Clin. Cancer Res., January 1, 2003; 9(1): 143 - 150. [Abstract] [Full Text] [PDF]

				S. Umemura, Y. Segawa, K. Fujiwara, I. Takata, N. Seki, Y. Tokuda, K. Eguchi, and K. Mandai A Case of Recurrent Metastatic Thymoma Showing a Marked Response to Paclitaxel Monotherapy Jpn. J. Clin. Oncol., July 1, 2002; 32(7): 262 - 265. [Abstract] [Full Text] [PDF]

				K. Osterlind Chemotherapy in small cell lung cancer Eur. Respir. J., December 1, 2001; 18(6): 1026 - 1043. [Abstract] [Full Text] [PDF]

				P. Thomas, O. Castelnau, D. Paillotin, H. Lena, G. Robinet, J. F. Muir, P. Delaval, S. Gouva, P. Balmes, F. Blanchon, et al. Phase II Trial of Paclitaxel and Carboplatin in Metastatic Small-Cell Lung Cancer: A Groupe Francais de Pneumo-Cancerologie Study J. Clin. Oncol., March 1, 2001; 19(5): 1320 - 1325. [Abstract] [Full Text] [PDF]

				C. Kosmas, N. B. Tsavaris, N. A. Malamos, M. Vadiaka, and C. Koufos Phase II Study of Paclitaxel, Ifosfamide, and Cisplatin as Second-Line Treatment in Relapsed Small-Cell Lung Cancer J. Clin. Oncol., January 1, 2001; 19(1): 119 - 126. [Abstract] [Full Text] [PDF]

				P. E. Postmus, H. Haaxma-Reiche, E. F. Smit, H. J. M. Groen, H. Karnicka, T. Lewinski, J. van Meerbeeck, M. Clerico, A. Gregor, D. Curran, et al. Treatment of Brain Metastases of Small-Cell Lung Cancer: Comparing Teniposide and Teniposide With Whole-Brain Radiotherapy--A Phase III Study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group J. Clin. Oncol., October 19, 2000; 18(19): 3400 - 3408. [Abstract] [Full Text] [PDF]

				N. Thatcher, D. J. Girling, P. Hopwood, R. J. Sambrook, W. Qian, and R. J. Stephens Improving Survival Without Reducing Quality of Life in Small-Cell Lung Cancer Patients by Increasing the Dose-Intensity of Chemotherapy With Granulocyte Colony-Stimulating Factor Support: Results of a British Medical Research Council Multicenter Randomized Trial J. Clin. Oncol., January 14, 2000; 18(2): 395 - 395. [Abstract] [Full Text] [PDF]